Levomilnacipran Extended-Release Capsules Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Capsules
Available Strengths: 20 mg, 40 mg, 80 mg, 120 mg
Reference Brands: Fetzima®(US)
Category: Antipsychotropic Drugs
Levomilnacipran Extended-Release Capsules is available in Extended-Release Capsules and strengths such as 20 mg, 40 mg, 80 mg, 120 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Levomilnacipran Extended-Release Capsules is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Levomilnacipran Extended-Release Capsules can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description: Levomilnacipran extended-release (ER) capsules are FDA-approved in the United States for the treatment of major depressive disorder (MDD) in adults. As a serotonin-norepinephrine reuptake inhibitor (SNRI), the ER formulation provides consistent plasma levels and once-daily dosing. U.S. regulations mandate boxed warnings for increased suicidal thoughts in young adults, GMP-compliant manufacturing, bioequivalence studies for generics, and post-marketing pharmacovigilance. In the European Union, levomilnacipran is not widely marketed, but companies may pursue national or decentralized procedures for approval. EU requirements include a comprehensive Risk Management Plan (RMP), clinical safety and efficacy data, and robust pharmacovigilance measures. For dossier-ready sourcing, visit Pharmatradz.com.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Clorazepate Dipotassium
Strength:
3.75 mg, 7.5 mg, 15 mg, 5 mg, 10 mg, 20 mg
Form: Tablets, Capsules
Reference Brands: Tranxene (USA), Tranxilium(EU)
View Details
Lumateperone
Strength:
10.5 mg, 21 mg, 42 mg
Form: Capsules
Reference Brands: Caplyta (USA)
View Details
Amoxapine
Strength:
25 mg, 50 mg, 100 mg, 150 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Amisulpride
Strength:
5 mg/2 mL, 50 mg, 100 mg, 200 mg
Form: Tablets / injectable solutions
Reference Brands: Barhemsys (USA), Solian (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
